Drug Profile
BP C1
Alternative Names: BP-C1Latest Information Update: 04 May 2022
Price :
$50
*
At a glance
- Originator Meabco
- Developer Meabco; Norwegian University of Life Sciences
- Class Antineoplastics; Platinum complexes
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Breast cancer
- No development reported Pancreatic cancer
Most Recent Events
- 26 Apr 2022 No development reported - Phase-II for Pancreatic cancer (Combination therapy, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in Egypt (IM)
- 06 Feb 2018 BP C1 is still in clinical development for Breast cancer (Meabco website, February 2018)
- 28 Dec 2017 No recent reports of development identified for clinical-Phase-Unknown development in Pancreatic-cancer in Denmark (IM)